HopeStage
Back to all studies
TerminatedNCT00369915

The Antidepressant Efficacy of the Anticholinergic Scopolamine

This study assesses depression symptoms.

Medication studyAges 18–55United States
The study in practice

Understand this study

What is this study about?

This study assesses depression symptoms.

Who could participate?

Listed age limits: 18 years to 55 years.

Listed locations
BethesdaSee all locations and recruitment
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.

Get this study by email

HopeStage may email me about this study.
Loading the security check...

What to know before participating

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Things to check before joining

Study start dateAugust 2006
Recruitment status
Terminated
Enrollment listed in the registry
17
Sponsor
National Institute of Mental Health (NIMH)
Sponsor type
Government agency
Study type
Drug
Intervention type
Drug
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Locations
United States
Age range
From 18 Years to 55 Years
Official registry ID
NCT00369915
Official title
Show the full official title

The Antidepressant Efficacy of the Anticholinergic Scopolamine

Recruitment & locations

Terminated

Bethesda

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

What is this study about?

This study assesses depression symptoms.

Who is behind this study?

The study sponsor is National Institute of Mental Health (NIMH), a government agency.

Does this study involve medication?

Yes. The study involves medication, including Scopolamine.

Who can participate?

Listed age limits: 18 years to 55 years.

Is this study still recruiting?

The registry lists this study as terminated.

Want to explore more studies?

Explore studies